Methotrexate induced pancytopenia is rare and concern for it should not limit its use [9]

Rheumatology

Volumn 45, Issue 3, 2006, Pages 361-

  Yazici, Yusuf ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE;

AGE DISTRIBUTION; DRUG INDUCED DISEASE; DRUG SAFETY; HUMAN; LETTER; LEUKOPENIA; OUTCOMES RESEARCH; PANCYTOPENIA; POLYPHARMACY; PREVALENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; METHOTREXATE; MIDDLE AGED; PANCYTOPENIA;

EID: 33644853624     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kei199     Document Type: Letter

References (4)

1. Lim AYN, Gaffney K, Scott DGI. Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 years. Rheumatology 2005;44:1051-5.
2. Weinblatt ME. Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol 1985;(Suppl. 12):35-9.
3. Yazici Y, Sokka T, Kautiainen H, Swearingen C, Kulman I, Pincus T. Long-term safety of methotrexate in routine clinical care: Discontinuation is unusual and rarely due to laboratory abnormalities. Ann Rheum Dis 2005;64:207-11.
4. Yazici Y, Erkan D, Harrison MJ, Nikolov NP, Paget SA. Methotrexate use in rheumatoid arthritis is associated with few clinically significant liver function test abnormalities. Clin Exp Rheumatol 2005;23:517-20.